1470P - First real life data on durvalumab after definitive concomitant chemoradiotherapy (cCRT) in unresectable stage (St) III non-small cell lung cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) temporary authorization of use (ATU)

• Published in: Annals of oncology Vol. 30; p. v597
• Main Authors: Avrillon, V., Bota Ouchlif, S., Merle, P., Pichon, E., Stancu, A.T., Chouaid, C., Sire, C., Boudabous, H., Lagrange, A., Sabatini, M., Eberst, G., Boisselier, P., Gourion, A., Lion, A., Lahouegue, A., Belkhiria, K., de La Porte, I., Urbieta, M., Mornex, F., Girard, N.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.10.2019

Among pts with St III unresectable NSCLC, only 15% are alive at 5 years with the historical Standard of Care (SoC) of definitive cCRT. Durvalumab, a human monoclonal anti-PD-L1 antibody, demonstrated efficacy in PFS and OS and was approved in Europe on September 2018 for the treatment of St III unre...